alexa Abstract | Multi Drug Resistant Shigella flexneri An Emerging Threat to Community

Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report Open Access


Shigellosis remains to be a considerable public health problem in many parts of the world and is endemic in India. Among the different studies conducted across India the isolation rate of Shigella varies from 2-6%, with Shigella flexneri to be the most prevalent serogroup. Unlike other acute diarrheal illness that require adequate fluid replacement (oral or intravenous), shigellosis additionally needs antimicrobial therapy to curtail the duration of illness and to prevent transmission to the close contacts. But like many other bacterial pathogens the frequency of antibiotic resistance among Shigella species is on the rise, and emergence of multi drug resistance (MDR) Shigella is a growing concern globally. The third generation cephalosporins and the fluoroquinolones are the mainstay of treatment in MDR cases, however emergence of strains resistant to even these drugs have been reported worldwide and also from various parts of India. Additionally strains of Shigella spp. that produce extended spectrum β-lactamase (ESBL), conferring resistance to third generation cephalosporins have also been reported thus limiting the treatment options for clinicians. We here report a case of 43 years old man suffering from diarrhea due to MDR strain of Shigella flexneri found resistant to all cephalosporins (1st, 2nd, and 3rd generation) and fluoroquinolones, susceptible only to meropenem, cefoperazone-sulbactam and piperacillin-tazobactam. Though the patient was treated successfully, but spread of such clones may pose a greater threat to the community and a comprehensive strategy for resistance control involving regulation of drug availability, antimicrobial drug quality assurance and discouraging antimicrobial abuse needs to be evolved.

To read the full article Peer-reviewed Article PDF image

Author(s): Deepak Juyal, Vikrant Negi, Munesh Sharma, Neelam Sharma


Ceftriaxone, diarrhea, ESBL, shigellosis, Pharmacy Practice,Molecular Drug Design,Multidrug-Resistant TB

Recommended Journals

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version